Start Time: 16:30 January 1, 0000 5:19 PM ET
Sage Therapeutics, Inc. (NASDAQ:SAGE)
Q4 2024 Earnings Conference Call
February 11, 2025, 16:30 PM ET
Company Participants
Barry Greene – CEO
Chris Benecchi – COO
Laura Gault – CMO
Mike Quirk – CSO
Ashley Kaplowitz – VP, IR and Capital Markets
Conference Call Participants
Ritu Baral – TD Cowen
Anupam Rama – JPMorgan
Paul Matteis – Stiefel
Tazeen Ahmad – Bank of America
Ami Fadia – Needham
Douglas Tsao – H.C. Wainwright
Uy Ear – Mizuho
Joel Beatty – Baird
Sumant Kulkarni – Canaccord
Joon Lee – Truist Securities
Operator
Good afternoon. Welcome to Sage Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Sage’s website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction, or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Ashley Kaplowitz, Vice President of Investor Relations and Capital Markets at Sage.
Ashley Kaplowitz
Good afternoon and thank you for joining Sage Therapeutics fourth quarter and full year 2024 financial results conference call. Before we begin, I encourage everyone to go to the Investors & Media section of our website at sagerx.com where you can find the press release and slides related to today’s call.
I would like to point out that we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today’s press release and in our SEC filings for additional details.
